Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!
Copenhagen, Denmark; July 24, 2013 – Genmab A/S (OMX: GEN) announced today that the Arzerra (ofatumumab) net sales during the second quarter of 2013 were GBP 17.8 million (approximately DKK 156 million). This figure consists of net sales in the U.S. of GBP 10.6 million and in the rest of the world of GBP 7.2 million. Under the terms of the collaboration with GlaxoSmithKline (GSK), Genmab expects to receive a royalty payment of approximately DKK 31 million.
Help employers find you! Check out all the jobs and post your resume.
